The Company and Basis of Presentation (Details) - USD ($) $ in Millions		1 Months Ended
	Apr. 17, 2020	Jun. 30, 2020
Otsuka Pharmaceutical Co Ltd | Exclusive Development And Commercialization Rights To Nexletol And Nexlizet Tablets
Collaborations with Third Parties
Upfront cash payment	$ 60.0
Potential additional future payments	$ 450.0
Otsuka Pharmaceutical Co Ltd | Exclusive Development And Commercialization Rights To Nexletol And Nexlizet Tablets | Minimum
Collaborations with Third Parties
Percentage of royalties to be received on the net sales	15.00%
Otsuka Pharmaceutical Co Ltd | Exclusive Development And Commercialization Rights To Nexletol And Nexlizet Tablets | Maximum
Collaborations with Third Parties
Percentage of royalties to be received on the net sales	30.00%
Daiichi Sankyo Europe GmbH ("DSE") | Amended License And Collaboration Agreement
Collaborations with Third Parties
Proceeds received upon completion of NUSTENDI MAA transfer		$ 150.0